AustriaTuberculosis profile
Population  2014 8.5 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.055 (0.054–0.056) 0.65 (0.64–0.66)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.01 (0–0.03)
Prevalence  (includes HIV+TB) 0.83 (0.35–1.5) 9.8 (4.1–18)
Incidence  (includes HIV+TB) 0.66 (0.58–0.75) 7.8 (6.8–8.8)
Incidence (HIV+TB only) 0.022 (0.017–0.028) 0.26 (0.2–0.33)
         
Case detection, all forms (%) 85 (75–97)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.7 (1.1–5.5) 37 (16–62)
MDR-TB cases among notified pulmonary
TB cases
12 (5–24) 11 (5–18)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 388   9
Pulmonary, clinically diagnosed 58   3
Extrapulmonary 104   2
       
Total new and relapse 564    
Previously treated, excluding relapses 18    
Total cases notified 582    
Among 563 new and relapse cases:
14 (2%) cases aged under 15 years; male:female ratio: 1.8
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 314 (81%) 20 (63%) 430
Laboratory-confirmed RR-/MDR-TB cases     50
Patients started on MDR-TB treatment ***     3
TB/HIV 2014 Number (%)
TB patients with known HIV status    
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (72) 617
Previously treated cases, excluding relapse, registered in 2013 (63) 16
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (60) 20
XDR-TB cases started on second-line treatment in 2012 (29) 7
Laboratories 2014  
Is second-line drug susceptibility testing available?  
Financing TB control 2015  
National TB programme budget (US$ millions)  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-09-30 Data: www.who.int/tb/data